IMP-321

Breast Carcinoma

Immutep S.A.S.protein_peptidePhase 2/3Active

CCC

55/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 81/ 100

Competitive context

208 Active assets in the Breast Carcinoma cohort.

Asset / Sponsor	Phase	Rating
TRASTUZUMAB SWOG Cancer Research Network	Phase 4	BBB
TAMOXIFEN Dartmouth-Hitchcock Medical Center	Phase 4	BBB
Zoledronate Washington University School of Medicine	Phase 4	BBB
Pertuzumab SWOG Cancer Research Network	Phase 3	BBB
Trastuzumab Deruxtecan SWOG Cancer Research Network	Phase 4	BBB

View all 50 →

Same molecule, other indications

IMP-321 is also rated in:

non-small cell lung carcinomaActive

BB

Indicative · Phase 3

66 / 100

breast adenocarcinomaDormant

B

Indicative · Phase 2

57 / 100

head and neck squamous cell carcinomaDormant

B

Indicative · Phase 2

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.